Maraviroc

Generic Name: Maraviroc

Brand Names: Celsentri, Selzentry

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₄₁F_₂N_₅O

CAS Number: 376348-65-1

Unique Ingredient Identifier: MD6P741W8A

Background: Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...

Indication: Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions: CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Phase 2

Completed

Conditions: Kaposi's Sarcoma

Interventions: Drug: Maraviroc

First Posted Date: 2011-01-13

Last Posted Date: 2021-03-05

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 13

Registration Number: NCT01276236

Locations: 🇺🇸
San Francisco General Hospital, Clinical Trials Unit, San Francisco, California, United States

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

Phase 4

Conditions: HIV-1 Infection

Interventions: Drug: Maraviroc

First Posted Date: 2010-11-05

Last Posted Date: 2010-11-19

Lead Sponsor: Hospital Clinic of Barcelona

Target Recruit Count: 60

Registration Number: NCT01235013

Locations: 🇪🇸
Hospital Clínic i Provincial, Barcelona, Spain

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen

Phase 4

Completed

Conditions: HIV Infection

Interventions: Drug: Maraviroc

First Posted Date: 2010-08-27

Last Posted Date: 2012-04-12

Lead Sponsor: St Stephens Aids Trust

Target Recruit Count: 12

Registration Number: NCT01190293

Locations: 🇬🇧
St Stephen's Centre, London, United Kingdom

Effects of Intensive cART During Acute/Early HIV Infection

Phase 2

Completed

Conditions: Acute HIV Infection

Interventions: Drug: raltegravir
Drug: maraviroc
Drug: emtricitabine 200mg /tenofovir 300mg
Drug: lopinavir 400 mg/ritonavir 100mg

First Posted Date: 2010-07-01

Last Posted Date: 2016-04-05

Lead Sponsor: University of Toronto

Target Recruit Count: 32

Registration Number: NCT01154673

Locations: 🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇨🇦
Maple Leaf Medical Clinic, Toronto, Ontario, Canada

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Maraviroc
Drug: Fosamprenavir/ritonavir
Drug: Maraviroc + Fosamprenavir/ritonavir

First Posted Date: 2010-06-09

Last Posted Date: 2011-02-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 14

Registration Number: NCT01140412

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Phase 1

Completed

Conditions: Hypertriglyceridemia

Interventions: Other: placebo
Drug: Maraviroc

First Posted Date: 2010-05-28

Last Posted Date: 2013-12-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT01133210

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Phase 1

Completed

Conditions: Healthy
HIV Infections

Interventions: Drug: Digoxin
Drug: Maraviroc

First Posted Date: 2010-01-26

Last Posted Date: 2011-04-07

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 12

Registration Number: NCT01056874

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Phase 4

Terminated

Conditions: HIV Infections

Interventions: Drug: Maraviroc
Drug: placebo

First Posted Date: 2010-01-14

Last Posted Date: 2011-11-01

Lead Sponsor: St Stephens Aids Trust

Target Recruit Count: 48

Registration Number: NCT01049204

Locations: 🇬🇧
St Stephen's Centre, London, United Kingdom

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Phase 4

Conditions: AIDS
Triple Class Failure
HIV-1 Adults Patients

First Posted Date: 2009-11-16

Last Posted Date: 2010-02-10

Lead Sponsor: Fundación Huésped

Target Recruit Count: 60

Registration Number: NCT01013987

Locations: 🇦🇷
Fundación Huésped, Ciudad de Buenos Aires, Argentina

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Phase 2

Completed

Conditions: HIV-1 Infection
HIV Infections

Interventions: Drug: maraviroc
Drug: darunavir
Drug: ritonavir

First Posted Date: 2009-10-12

Last Posted Date: 2014-09-05

Lead Sponsor: Northwestern University

Target Recruit Count: 25

Registration Number: NCT00993148

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy